{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:31Z","timestamp":1786119331154,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/mbc.0b013e3283488494","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T18:47:42Z","timestamp":1317754062000},"page":"457-462","source":"Crossref","is-referenced-by-count":9,"title":["Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia"],"prefix":"10.1097","volume":"22","author":[{"given":"Argirios E.","family":"Tsantes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K.","family":"Nikolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Tsirigotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Zoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Zomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Kapsimali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Kopterides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Chondropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dervenoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Mantzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF01788127","article-title":"Primary thrombocythemia: diagnosis, clinical manifestations and management.","volume":"67","author":"van Genderen","year":"1993","journal-title":"Ann Hematol"},{"key":"R2-2-20210203","first-page":"51","article-title":"Spontaneous proliferative megakaryopoiesis and platelet hyperactivity in essential thrombocythemia: is thrombopoietine the link Ann H","volume":"79","author":"Bellucci","year":"2000","journal-title":"ematol"},{"issue":"Suppl 1","key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428199609074363","article-title":"Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative disorders.","volume":"22","author":"Finazzi","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcp\/91.6.647","article-title":"Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis.","volume":"91","author":"Raman","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1309\/K58EWK4HPD51U3BE","article-title":"Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100.","volume":"123","author":"Cesar","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V64.1.1.1","article-title":"Bleeding and thrombosis in the myeloproliferative disorders.","volume":"64","author":"Schafer","year":"1984","journal-title":"Blood"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.thromres.2009.06.030","article-title":"Tsantes , Dimoula , Bonovas S, Mantzios G, Tsirigotis P, Zoi K, et al. The role of the platelet function analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis.","volume":"125","year":"2010","journal-title":"Thromb Res"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1046\/j.1365-2141.1996.d01-1729.x","article-title":"The reduction of large von Willebrand factor multimers in plasma in essential thrombocythemia is related to the platelet count.","volume":"93","author":"Van Genderen","year":"1996","journal-title":"Br J Haematol"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1076029606291428","article-title":"Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures.","volume":"12","author":"Sucker","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2008.03.008","article-title":"Monitoring aspirin treatment in patients with thrombocytosis: comparison of the platelet function analyzer (PFA)-100 with optical aggregometry.","volume":"123","author":"Tsantes","year":"2008","journal-title":"Thromb Res"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.","volume":"80","author":"Landofi","year":"1992","journal-title":"Blood"},{"key":"R16-2-20210203","first-page":"1125","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia.","volume":"74","author":"Rocca","year":"1995","journal-title":"Thromb Haemost"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1532\/IJH97.E0316","article-title":"Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia vera.","volume":"79","author":"Karakantza","year":"2004","journal-title":"Int J Hematol"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-2007-996106","article-title":"Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism - thesis 1981, Rotterdam.","volume":"23","author":"Michiels","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199509213331216","article-title":"Hydroxyurea in essential thrombocythemia.","volume":"333","author":"Van Genderen","year":"1995","journal-title":"N Engl J Med"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/107602969900500408","article-title":"Aspirin and platelet lowering agents for the prevention of vascular complications in essential thrombocythemia.","volume":"5","author":"Michiels","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.1986.tb07497.x","article-title":"Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis.","volume":"63","author":"Fabris","year":"1986","journal-title":"Br J Haematol"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01698487","article-title":"Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia with platelet count.","volume":"69","author":"Van Genderen","year":"1994","journal-title":"Ann Hematol"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","article-title":"Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.","volume":"82","author":"Budde","year":"1993","journal-title":"Blood"},{"key":"R24-2-20210203","first-page":"385","article-title":"The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link Semin Thromb H","volume":"23","author":"Van Genderen","year":"1997","journal-title":"emost"},{"key":"R25-2-20210203","first-page":"853","article-title":"Improvement of platelet aggregation abnormalities in thrombocytosis after thrombocytopheresis.","volume":"108","author":"Fabris","year":"1981","journal-title":"Folia Haematol Int Mag Klin Morphol Blutforsch"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von Willebrand disease in patients with high platelet counts.","volume":"23","author":"Budde","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index A meta-analysis of clinical outcomes in essential thrombocythemia.","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12185-008-0129-9","article-title":"Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.","volume":"88","author":"Hattori","year":"2008","journal-title":"Int J Hematol"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.","volume":"84","author":"Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001721-201109000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:02:45Z","timestamp":1786039365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-201109000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e3283488494","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}